The characteristics of patients receiving fluvastatin sodium

Reviews in Contemporary Pharmacotherapy

Volumn 7, Issue 4, 1996, Pages 183-190

  Deslypere, J P ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0004615236     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Amorosa L. Efficacy and safety of fluvastatin in special patient groups. Clin Cardiol 1994; 17 (Suppl 4): 21-27.
2. Appel S, Rüfenacht T, Kalafsky G, Tetzloff W, Kallay Z, Hitzenberger G, Kutz K. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am J Cardiol 1995; 76: 29A-32A.
3. Arca M, Vega CL, Grundy SM. Hypercholesterolemia in postmenopausal women: metabolic defects and response to low dose lovastatin. JAMA 1994; 271: 453-459.
4. Attman P, Samuelsson O, Alanpovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-592.
5. Baggio G, De Candia O, Forte P et al. Efficacy and safety of fluvastatin, a new HMG Co A reductase inhibitor, in elderly hypercholesterolemic women. Drugs 1994; 47 (Suppl 2): 59-63.
6. Bradford R, Dounton M, Chremos A. Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. Ann Intern Med 1993; 118: 850-855.
7. Brunner FP, Fassbinder W, Broyer M et al. Survival on renal replacement therapy: data for the EDTA Registry. Nephrol Dial Transplant 1988; 3: 109-122.
8. Cheng H, Rogers J, Sweany A. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharmaceut Res 1992; 9: 1629-1633.
9. Coleman M, Key T, Wang D. A prospective study of obesity, lipids, apolipoproteins and ischemic heart disease in women. Atherosclerosis 1992; 92: 177-185.
10. Davidson M. Fluvastatin long-term extension trial (FLUENT): summary of efficacy and safety. Am J Med 1994; 96 (Suppl A): 41-44.
11. Deslypere JP. Clinical implications of the biopharmaceutical properties of fluvastatin. Am J Cardiol 1994; 73: 12-17.
12. Deslypere JP. The role of HMG-CoA reductase inhibitors in the treatment of hyperlipidemia: a review of fluvastatin. Curr Ther Res 1995; 56: 111-128.
13. Eliav O, Schurr D, Pfister P, Friedlander Y, Leitersdorf E. High dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia. Am J Cardiol 1995; 76: 76A-79A.
14. Fontbonne A, Eschwege E, Cambien F et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris prospective study. Diabetologia 1989; 32: 300-304.
15. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990; 13: 153-169.
16. Goldberg R, Roth D. A preliminary report of the safety and the efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76: 107A-109A.
17. Harris KP, Russell GI, Parvin SD, Veitch PS, Walls J. Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients. Br Med J 1986; 292: 16.
18. Holdaas H, Hartmann A, Stenstrom J, Dahl K, Borge M, Pfister P. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76: 102A-106A.
19. Jacobsen T, Jokubeitis L, Amorosa L. Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy. Am J Med 1994; 96 (Suppl 6A): 64-68.
20. Kannel WB, Sorbie P, McNamara P. Prognosis after initial myocardial infarction: the Framingham study. Am J Cardiol 1979; 44: 53-59.
21. Kasiske BL, Umen AJ. Persistent hyperlipidemia in renal transplant patients. Medicine 1987; 66: 309-316.
22. Knopp R, Frohlich J, Jokubaitis L, Danson K, Broyles F, Gomez-Coronado D. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am J Med 1994; 96 (Suppl 6A): 69-78.
23. Koizumi J, Haraki T, Yagi K et al. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia. Am J Cardiol 1995; 76: 47A-50A.
24. Leitersdorf E. Gender related response to fluvastatin in patients with heterozygous familial hypercholesterolemia. Drugs 1994; 47 (Suppl 2): 54-58.
25. Leitersdorf E, Eisenberg S, Eliav O et al. Genetic determinants of responsiveness to the HMG Co A reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 1993; 87 (Suppl 3): 35-44.
26. Leitersdorf E, Muretti E, Eliav O, Peters T. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Am J Cardiol 1995; 76: 84A-88A.
27. Levy R, Troendle A, Fattu J. A quarter century of drug treatment of dyslipoproteinemia with a focus on the new HMG CoA reductase inhibitor fluvastatin. Circulation 1993; 87 (Suppl 3): 45-53.
28. Lintott C, Scott R, Bremer J, Shand B. Fluvastatin for dyslipoproteinemia with or without concomitant chronic renal insufficiency. Am J Cardiol 1995; 76: 97A-101A.
29. Peters TK, Mehra M, Muratti EN. Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database. Am J Hypertens 1993a; 6 (Suppl): 340-345.
30. Peters TK, Jewitt-Harris J, Mehra M, Muratti E. Safety and tolerability of fluvastatin with concomitant use of antihypertensive agents. An analysis of a clinical trial database. Am J Hypertens 1993b; 6: 346S-352S.
31. Peters TK, Muratti E, Mehra M. Efficacy and safety of fluvastatin in women with primary hypercholesterolemia. Drugs 1994a; 47 (Suppl 2): 64-72.
32. Peters TK, Muratti E, Mehra M. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database. Am J Med 1994b; 96 (Suppl 6A): S79-S83.
33. Pirsch JD, Voss BJ, Roecker EB et al. Predictive factors for immunologic graft failure in cadaver renal transplant recipients. Transplant Proc 1991; 23: 1282-1283.
34. Reyner B, Byrne M, van Zijl-Smit R. Treatment of hyperlipidemia with simvastatin and diet vs diet alone in idiopathic membranous nephropathy. Nephrol Dial Transplant 1994; 9: 963.
35. Samuelsson O, Aurell M, Knight-Gibson C, Alanporic P, Attman PO. Apo B-containing lipoproteins and the progression of renal insufficiency. Nephron 1993; 63: 279-285.
36. Sheer C, Franklin F, Stinnett S. Expanded clinical evaluation of lovastatin (EXCEL) study results: effect of patient characteristics in lovastatin induced changes in plasma concentrations of lipids and lipoproteins. Circulation 1992:85:453-459.
37. Shohat J, Boner G. Role of lipids in the progression of renal disease in chronic renal failure: evidence from animal studies and pathogenesis. Isr J Med Sci 1993; 29: 228-239.
38. Smith H, Jokubaitis L, Troendle A, Hwang D, Robinson W. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 1993; 6 (Suppl): 375S-382S.
39. Yuan J, Tsai M, Hegland J, Hunninghake D. Effects of fluvastatin, an HMG CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 1991; 87: 147-157.